Two recent MPACT subanalyses (Chiorean et al. and Ramanathan et al. *Ann Oncol*. 2016) demonstrated evidence that decreases from baseline in carbohydrate antigen 19-9 (CA19-9) and tumor uptake of radioactively labeled glucose (^18^F-FDG) as measured by positron emission tomography (PET) imaging were each significantly associated with longer overall survival (OS) in patients who received first-line treatment with *nab*-paclitaxel plus gemcitabine or gemcitabine for metastatic pancreatic cancer \[[@MDW177C1], [@MDW177C2]\]. These modalities are complementary approaches to monitor treatment efficacy in most patients. However, we raised the question of whether tumor response measured by PET could predict outcome for a subset of patients (15%--20%) with pancreatic cancer who do not secrete elevated levels of CA19-9 \[[@MDW177C3], [@MDW177C4]\]. In the MPACT trial, more patients experienced a metabolic response (MR) measured by PET imaging than a tumor response measured by computed tomography. PET imaging may be particularly valuable to predict outcomes in patients without elevated baseline CA19-9 levels.

We carried out a post hoc, pooled treatment-arm analysis of OS by PET response in patients without elevated CA19-9 levels at baseline (defined as \<37 U/ml). Results for OS by MR (defined by European Organization for the Research and Treatment of Cancer \[EORTC\] criteria \[[@MDW177C5]\]) are summarized in Table [1](#MDW177TB1){ref-type="table"}. MRs at week 8 and at best response during the study were each significantly associated with longer OS in patients with no CA19-9 elevation at baseline. Specifically, the median OS in patients with an MR at week 8 was 5.2 months longer than that in patients without one. In addition, patients with an MR at any time during the study had a nearly twofold longer median OS than those without one.Table 1.Overall survival by metabolic response in patients without elevated baseline CA19-9 levels treated with *nab*-paclitaxel plus gemcitabine or gemcitabine alone (pooled)Patients without elevated CA19-9 levels at baseline in the PET cohortHR (*P-*value)Yes PET MRNo PET MRWeek 8*n* = 21*n* = 17Median OS, months13.28.00.34 (0.001)(95% CI)(9.20--17.05)(3.38--14.69)One-year survival rate52%35%Best response during treatment*n* = 24*n* = 16Median OS, months13.66.90.31 (0.003)(95% CI)(9.26--22.83)(3.38--10.22)One-year survival rate58%25%[^1]

These results illustrate that PET imaging may serve as a valuable tool to monitor treatment response in the subset of patients without elevated CA19-9 levels at baseline. Future trials may examine this issue more systematically as a preplanned end point.
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